OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Weinberg Discusses the Use of FOLFIRINOX in Older Patients With Metastatic Pancreatic Cancer

February 26th 2019

Benjamin Weinberg, MD, assistant professor of medicine, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, discusses the use of FOLFIRINOX in older patients with metastatic pancreatic cancer.

Dr. Slovin Discusses Risk Factors for ADT-Associated Cardiac Complications in Prostate Cancer

February 26th 2019

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses risk factors for androgen deprivation therapy (ADT)-associated cardiac complications in prostate cancer.

Dr. Cerfolio on the Role of Surgery in Lung Cancer

February 26th 2019

Robert J. Cerfolio, MD, director of the Lung Cancer Center, chief of clinical thoracic surgery, NYU Langone’s Perlmutter Cancer Center, discusses the role of surgery in lung cancer.

Dr. Smaglo Discusses the FDA Approval of TAS-102 for Gastric/GEJ Cancer

February 26th 2019

Brandon G. Smaglo, MD, FACP, assistant professor of internal medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the FDA approval of TAS-102 (trifluridine/tipiracil; Lonsurf) in gastric/gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Subramanian Discusses Tumor Biology in Lung Cancer

February 23rd 2019

Janakiraman Subramanian, MD, a medical oncologist and director of thoracic oncology and director of the Center for Precision Medicine at Saint Luke’s Cancer Institute, discusses tumor biology in lung cancer.

Dr. Chung on the COMPASS Trial in Pancreatic Cancer

February 23rd 2019

Vincent Chung, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, director of the Phase I Program, City of Hope, discusses the COMPASS trial in pancreatic cancer.

Dr. Yu Discusses Treatment Strategies for Patients With Oligometastatic Prostate Cancer

February 23rd 2019

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment strategies for patients with oligometastatic prostate cancer.

Dr. Agarwal Discusses Results of KEYNOTE-426 in mRCC

February 23rd 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses findings from the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

Dr. Eng on Recognizing Tumor Sidedness in mCRC

February 23rd 2019

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses recognizing tumor sidedness in the treatment of patients with metastatic colorectal cancer.

Dr. Landen on Molecular Subtypes of Ovarian Cancer

February 23rd 2019

Chip Landen, MD, associate professor, Division of Gynecologic Oncology, University of Virginia Health System, discusses the molecular subtypes of ovarian cancer.

Dr. Cohen Discusses Research Questions in Head and Neck Cancer

February 22nd 2019

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses remaining questions regarding the use of immunotherapy in head and neck cancer that still need to be addressed.

Dr. Tawbi on Unmet Needs in Melanoma

February 22nd 2019

Hussein A. Tawbi, MD, PhD, associate professor, The University of Texas MD Anderson Cancer Center, discusses unmet needs in melanoma.

Dr. Shao on Prognosis of Patients With HER2+ Breast Cancer

February 22nd 2019

Theresa Shao, MD, assistant professor of hematology-oncology, Icahn School of Medicine, Tisch Cancer Institute, Mount Sinai Health System, discusses the prognosis of patients with HER2-positive breast cancer.

Dr. Verstovsek on Toxicity Profile of Ruxolitinib in MPNs

February 22nd 2019

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the toxicity profile of ruxolitinib in the treatment of patients with myeloproliferative neoplasms.

Dr. Socinski on Current State of Treatment in NSCLC

February 22nd 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses the current state of treatment for patients with non–small cell lung cancer.

Dr. Jhaveri Discusses the Potential of Immunotherapy in TNBC

February 22nd 2019

Komal Jhaveri, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the potential for immunotherapy in the treatment of patients with triple-negative breast cancer (TNBC) based on results from the IMpassion130 trial.

Dr. Lee on the Benefit of Cytoreductive Surgery in Metastatic Colorectal Cancer

February 21st 2019

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate professor of surgical oncology, City of Hope, discusses the benefit of cytoreductive surgery in the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Ganjoo on the Treatment of Metastatic Uterine Leiomyosarcoma

February 21st 2019

Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses the treatment of patients with metastatic uterine leiomyosarcoma.

Dr. Kambhampati on Challenges in CLL

February 21st 2019

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Cancer Institute, HCA Midwest Health, discusses the patient populations that remain an unmet need in chronic lymphocytic leukemia (CLL).

Dr. Goldberg on Managing CNS Metastases in Oncogene-Driven NSCLC

February 21st 2019

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses strategies for managing central nervous system metastases in patients with oncogene-driven non–small cell lung cancer.